<DOC>
	<DOCNO>NCT01979822</DOCNO>
	<brief_summary>The clinical study aim investigate number predefined complication first six month implantation implantable LENUS Pro® medication pump intravenous application treprostinil sodium patient PAH . The manufacturer Tricumed GmbH , Germany ; exclusive marketing right : OMT GmbH &amp; Co KG 78665 Frittlingen , Germany .</brief_summary>
	<brief_title>LenusPro Safety ( LPS ) Study Patients With PH</brief_title>
	<detailed_description>The previously use fully implantable pump improve development additional safety option ( e.g . acoustic occlusion alarm ) use patient PH . In meantime , pump ( manufacturer : Tricumed GmbH , Germany , exclusively market right : OMT GmbH &amp; Co KG , 78665 Frittlingen , Germany ) offer option meet requirement use treat PH patient . It base constant flow system consist gas drive micro-infusion via chip capillary . The medication fill titanium reservoir via so-called filling septum ( silicon membrane ) . The membrane puncture percutaneously special needle specially trained personnel fill aseptic condition . Various safety option ensure continuous flow rate medication signalize malfunction . If catheter occlusion signalize , catheter rinse second septum pump percutaneous puncture without empty medication reservoir . The pump available two size ( 20 ml 40 ml filling volume ) . The flow rate set 20 ml pump 1.0 ml/ 24 hour , refill require every 19 20 day . The flow rate set 40 ml pump 2.3 ml/ 24 hour , refill require every 29 30 day . Initial experience use pump show good result 3 year use ( minor complication implantation , pump defect long-term usage , reliable fill outpatient condition ) . R. Ewert ; M. Halank , L. Bruch ; H.A . Ghofrani . The implantable pump - new option intravenous therapy patient severe pulmonary hypertension . Am J Respir Crit Care 2012 ; 186:1196-98 Steringer-Mascherbauer R. , Eder V. , Ebner Ch . et al . First experience intravenous treprostinil deliver implantable pump ( Lenus Pro® ) fill interval 28 day patient pulmonary arterial hypertension ( PAH ) - case report . ATS Poster Desole S , Velik-Salchner C , Fraedrich G et al . Subcutaneous implantation new intravenous pump system prostacyclin treatment patient pulmonary arterial hypertension . Heart Lung 2012 Aug 21 . [ Epub ahead print ] Such pump implant 90 patient various European country past 3 year . Experience show patient select implantation FC II-IV combination therapy ( 2-3 specific PH-medications ) . The previous medication either regard insufficient respect cardiopulmonary stabilization side effect therapy intolerable . The latter apply particularly patient subcutaneous delivery treprostinil fairly large dos . Given previous application LENUS Pro® pump context individualize heal attempt , initiator plan study consider necessary ascertain safety fully implantable pump system control prospective study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patient Patient age ≥ 18 year Patient ( patient 's legally authorize representative ) willing able provide write informed consent Patient willing able comply protocol , include require followup visit Patient diagnose Pulmonary Arterial Hypertension ( World Health Organization ( WHO ) Category Group 1 ( WHO Clinical classification system ) , include Idiopathic ( IPAH ) , Heritable PAH ( HPAH ) ( Familial PAH ) , PAH associate disease ( APAH ) , Patient receive continuous infusion treprostinil via subcutaneous intravenous delivery use external pump system Patient stable clinical condition und previous specific PH medication retain unchanged past 3 week Patient 's anticoagulation therapy manage permit safe device implantation Pregnancy , nurse Women childbearing potential reliable safe form contraception Patient diagnose PH etiology different inclusion criterion , Patient diagnose chronic kidney disease ( estimate GFR &lt; 30 ) within ninety ( 90 ) day prior Baseline visit ; chronic kidney disease define last expect last three ( 3 ) month . Hepatic insufficiency ( Child C ) Patient person whose body size sufficient accept implantable pump bulk weight determine implant surgeon Unacceptably high anesthetic risk determine treat anesthesiologist Concomitant medication underlie disease associate increased infection risk ( e.g. , intravenous drug abuse , diabetic gangrene ) Patient stable condition , especially manifestation decompensated right heart failure within three week prior Baseline visit Patients significantly increase bleed risk due comorbidities ( e.g . hereditary F VIII deficiency , myeloproliferative neoplasm ) Estimated life expectancy &lt; 6 month due comorbidities ( e.g . terminal malignancy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>medication pump , complication , safety observation</keyword>
</DOC>